sorafenib has been researched along with temozolomide in 21 studies
| Studies (sorafenib) | Trials (sorafenib) | Recent Studies (post-2010) (sorafenib) | Studies (temozolomide) | Trials (temozolomide) | Recent Studies (post-2010) (temozolomide) |
|---|---|---|---|---|---|
| 6,520 | 730 | 5,251 | 6,014 | 826 | 4,331 |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 5 (23.81) | 29.6817 |
| 2010's | 16 (76.19) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Chen, M; Hu, C; Suzuki, A; Thakkar, S; Tong, W; Yu, K | 1 |
| Liu, Y; Xu, Z; Zhao, SJ | 1 |
| Clynes, M; Crown, J; Eustace, AJ; O'Donovan, N | 1 |
| Hwu, P; Kim, K; Lazar, AJ; Quintás-Cardama, A; Ross, M; Woodman, SE | 1 |
| Lee, F; Richmond, A; Smykla, R; Thu, YM; Yang, J; Zaja-Milatovic, S | 1 |
| Walker, JG | 1 |
| Pappo, A; Paulino, AC | 1 |
| Subbiah, V; Wolff, JE | 1 |
| Bigner, DD; Desjardins, A; Friedman, AH; Friedman, HS; Gururangan, S; Herndon, JE; Janney, D; Marcello, J; McLendon, RE; Peters, K; Reardon, DA; Sampson, JH; Vredenburgh, JJ | 1 |
| Clark, BL; Ervin, T; Friedman, E; Hainsworth, JD; Lamar, RE; Murphy, PB; Priego, V | 1 |
| Ali-Osman, F; Augustine, CK; Beasley, GM; Burchette, J; Jung, SH; McMahon, N; Padussis, J; Pruitt, SK; Selim, MA; Toshimitsu, H; Tyler, DS; Yoo, JS; Yoshimoto, Y; Zipfel, PA | 1 |
| Cawkwell, L; Little, SJ; Maraveyas, A; Murray, A; Stanley, P | 1 |
| Amaravadi, RK; Li, LZ; Lum, JJ; Ma, XH; McAfee, QW; Nathanson, KL; Piao, S; Wang, D | 1 |
| Boulinguez, S | 1 |
| Andrews, DW; Camphausen, K; Den, RB; Dicker, AP; Dougherty, E; Friedman, DP; Glass, J; Green, MR; Hegarty, S; Hyslop, T; Kamrava, M; Lawrence, YR; Marinucchi, M; Sheng, Z; Werner-Wasik, M | 1 |
| Amoroso, D; Andreuccetti, M; Falcone, A; Fontana, A; Galli, C; Galli, L; Landi, L; Lombardi, G; Porta, C; Zagonel, V; Zustovich, F | 1 |
| Ben Aissa, A; Bodmer, A; Dietrich, PY; Dunkel, N; Espeli, V; Hottinger, AF; Hundsberger, T; Mach, N; Schaller, K; Squiban, D; Vargas, MI; Weber, DC | 1 |
| Dorsch-Vogel, K; Gabrielson, A; He, AR; Jha, R; Marshall, JL; Pishvaian, MJ; Smaglo, B; Tesfaye, AA; Wang, H | 1 |
| Buchfelder, M; Eyüpoglu, IY; Rauh, M; Savaskan, NE; Sehm, T; Wiendieck, K | 1 |
| Bądziul, D; Jakubowicz-Gil, J; Langner, E; Rzeski, W; Wertel, I; Zając, A | 1 |
| Franken, MG; Gheorghe, M; Haanen, JBAG; Leeneman, B; Uyl-de Groot, CA; van Baal, PHM | 1 |
3 review(s) available for sorafenib and temozolomide
| Article | Year |
|---|---|
DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.
Topics: Chemical and Drug Induced Liver Injury; Databases, Factual; Drug Labeling; Humans; Pharmaceutical Preparations; Risk | 2016 |
1,2,3-Triazole-containing hybrids as potential anticancer agents: Current developments, action mechanisms and structure-activity relationships.
Topics: Antineoplastic Agents; Humans; Molecular Structure; Neoplasms; Structure-Activity Relationship; Triazoles | 2019 |
A systematic literature review and network meta-analysis of effectiveness and safety outcomes in advanced melanoma.
Topics: Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Azetidines; Benzimidazoles; Cancer Vaccines; Carboplatin; Dacarbazine; gp100 Melanoma Antigen; Humans; Hydrazines; Imidazoles; Interleukin-2; Ipilimumab; Lenalidomide; Melanoma; Network Meta-Analysis; Nitrosourea Compounds; Nivolumab; Organophosphorus Compounds; Oximes; Paclitaxel; Piperidines; Progression-Free Survival; Proportional Hazards Models; Pyridones; Pyrimidinones; Skin Neoplasms; Sorafenib; Survival Rate; Temozolomide; Treatment Outcome; Vemurafenib | 2019 |
6 trial(s) available for sorafenib and temozolomide
| Article | Year |
|---|---|
Effect of CYP3A-inducing anti-epileptics on sorafenib exposure: results of a phase II study of sorafenib plus daily temozolomide in adults with recurrent glioblastoma.
Topics: Adult; Aged; Anticonvulsants; Antineoplastic Combined Chemotherapy Protocols; Benzenesulfonates; Brain Neoplasms; Cytochrome P-450 CYP3A; Dacarbazine; Disease-Free Survival; Female; Glioblastoma; Humans; Kaplan-Meier Estimate; Male; Middle Aged; Neoplasm Recurrence, Local; Niacinamide; Phenylurea Compounds; Pyridines; Recurrence; Sorafenib; Temozolomide | 2011 |
Concurrent radiotherapy and temozolomide followed by temozolomide and sorafenib in the first-line treatment of patients with glioblastoma multiforme.
Topics: Adult; Aged; Antineoplastic Agents, Alkylating; Antineoplastic Combined Chemotherapy Protocols; Benzenesulfonates; Brain Neoplasms; Combined Modality Therapy; Dacarbazine; Female; Glioblastoma; Humans; Male; Middle Aged; Niacinamide; Phenylurea Compounds; Pyridines; Sorafenib; Temozolomide | 2010 |
A phase I study of the combination of sorafenib with temozolomide and radiation therapy for the treatment of primary and recurrent high-grade gliomas.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; Cell Line, Tumor; Cell Survival; Chemoradiotherapy; Dacarbazine; Female; Glioma; Humans; Male; Maximum Tolerated Dose; Middle Aged; Neoplasm Proteins; Neoplasm Recurrence, Local; Niacinamide; Phenylurea Compounds; Radiotherapy Dosage; Sorafenib; Temozolomide; Vascular Endothelial Growth Factor A | 2013 |
Sorafenib plus daily low-dose temozolomide for relapsed glioblastoma: a phase II study.
Topics: Adult; Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; Dacarbazine; Disease Progression; Dose-Response Relationship, Drug; Drug Administration Schedule; Female; Glioblastoma; Humans; Magnetic Resonance Imaging; Male; Middle Aged; Niacinamide; Phenylurea Compounds; Recurrence; Sorafenib; Survival Analysis; Temozolomide; Time Factors | 2013 |
Phase I study of sorafenib combined with radiation therapy and temozolomide as first-line treatment of high-grade glioma.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; Chemoradiotherapy; Dacarbazine; Disease-Free Survival; Female; Glioblastoma; Humans; Male; Maximum Tolerated Dose; Middle Aged; Niacinamide; Phenylurea Compounds; Sorafenib; Temozolomide; Treatment Outcome | 2014 |
Phase II study of temozolomide and veliparib combination therapy for sorafenib-refractory advanced hepatocellular carcinoma.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Benzimidazoles; Carcinoma, Hepatocellular; Dacarbazine; Disease-Free Survival; DNA Methylation; DNA Repair; DNA, Neoplasm; Drug Resistance, Neoplasm; Fatigue; Female; Genes, BRCA1; Genes, BRCA2; Humans; Kaplan-Meier Estimate; Liver Neoplasms; Male; Middle Aged; Niacinamide; Phenylurea Compounds; Poly(ADP-ribose) Polymerase Inhibitors; Salvage Therapy; Sorafenib; Temozolomide; Treatment Failure | 2015 |
12 other study(ies) available for sorafenib and temozolomide
| Article | Year |
|---|---|
Preclinical evaluation of dasatinib, a potent Src kinase inhibitor, in melanoma cell lines.
Topics: Antineoplastic Agents; Apoptosis; Benzenesulfonates; Blotting, Western; Cell Cycle; Cell Line, Tumor; Cell Movement; Cell Proliferation; Dacarbazine; Dasatinib; Drug Screening Assays, Antitumor; Drug Synergism; Focal Adhesion Protein-Tyrosine Kinases; Humans; Melanoma; Neoplasm Invasiveness; Niacinamide; Phenylurea Compounds; Protein Kinase Inhibitors; Proto-Oncogene Proteins pp60(c-src); Pyridines; Pyrimidines; Receptor, EphA2; Sorafenib; Temozolomide; Thiazoles | 2008 |
Complete response of stage IV anal mucosal melanoma expressing KIT Val560Asp to the multikinase inhibitor sorafenib.
Topics: Aged; Antineoplastic Agents; Anus Neoplasms; Benzenesulfonates; Dacarbazine; Humans; Male; Melanoma; Neoplasm Staging; Niacinamide; Phenylurea Compounds; Proto-Oncogene Proteins c-kit; Pyridines; Sorafenib; Temozolomide; Treatment Outcome | 2008 |
Molecular determinants of melanoma malignancy: selecting targets for improved efficacy of chemotherapy.
Topics: Animals; Antineoplastic Agents; Benzenesulfonates; Biomarkers, Tumor; Dacarbazine; Drug Delivery Systems; Drug Synergism; Female; Gene Expression Regulation, Neoplastic; Humans; Imidazoles; Melanoma; Mice; Mice, Inbred BALB C; Mice, Nude; Models, Biological; Niacinamide; Phenylurea Compounds; Pyridines; Quinoxalines; Skin Neoplasms; Sorafenib; Substrate Specificity; Temozolomide; Treatment Outcome; Tumor Cells, Cultured; Xenograft Model Antitumor Assays | 2009 |
Diagnosis and management of leptomeningeal disease.
Topics: Adult; Antineoplastic Agents, Alkylating; Benzenesulfonates; Dacarbazine; Female; Humans; Meningeal Carcinomatosis; Meningeal Neoplasms; Niacinamide; Phenylurea Compounds; Prevalence; Prognosis; Protein Kinase Inhibitors; Pyridines; Sorafenib; Temozolomide | 2009 |
Alveolar rhabdomyosarcoma of the extremity and nodal metastasis: Is the in-transit lymphatic system at risk?
Topics: Antineoplastic Combined Chemotherapy Protocols; Benzenesulfonates; Camptothecin; Child; Combined Modality Therapy; Cyclophosphamide; Dacarbazine; Dactinomycin; Etoposide; Fatal Outcome; Female; Foot; Groin; Humans; Ifosfamide; Irinotecan; Lymph Node Excision; Lymphatic Metastasis; Lymphatic System; Male; Niacinamide; Phenylurea Compounds; Pyridines; Radiotherapy, Adjuvant; Radiotherapy, High-Energy; Rhabdomyosarcoma, Alveolar; Salvage Therapy; Soft Tissue Neoplasms; Sorafenib; Temozolomide; Thigh; Vincristine | 2009 |
Rapid response to therapy of neurocutaneous melanosis with leptomeningeal melanoma.
Topics: Antineoplastic Combined Chemotherapy Protocols; Benzenesulfonates; Child, Preschool; Cyclophosphamide; Dacarbazine; Female; Humans; Melanoma; Melanosis; Meningeal Neoplasms; Neurocutaneous Syndromes; Niacinamide; Phenylurea Compounds; Pyridines; Sorafenib; Temozolomide; Treatment Outcome | 2010 |
Sorafenib, a multikinase inhibitor, enhances the response of melanoma to regional chemotherapy.
Topics: Animals; Antineoplastic Agents, Alkylating; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Benzenesulfonates; Blotting, Western; Butadienes; Cell Line, Tumor; Cell Survival; Dacarbazine; Drug Synergism; Extracellular Signal-Regulated MAP Kinases; Female; Humans; Melanoma; Melphalan; Mutation; Myeloid Cell Leukemia Sequence 1 Protein; Niacinamide; Nitriles; Phenylurea Compounds; Protein Kinase Inhibitors; Proto-Oncogene Proteins B-raf; Proto-Oncogene Proteins c-bcl-2; Pyridines; Rats; Rats, Nude; Sorafenib; Temozolomide; Tumor Burden; Xenograft Model Antitumor Assays | 2010 |
Sorafenib enhances the in vitro anti-endothelial effects of low dose (metronomic) chemotherapy.
Topics: Angiogenesis Inhibitors; Antineoplastic Combined Chemotherapy Protocols; Benzenesulfonates; Cell Line, Tumor; Cell Proliferation; Dacarbazine; Drug Administration Schedule; Endothelial Cells; Etoposide; Humans; In Vitro Techniques; Neovascularization, Pathologic; Niacinamide; Paclitaxel; Phenylurea Compounds; Pyridines; Sorafenib; Temozolomide | 2010 |
Measurements of tumor cell autophagy predict invasiveness, resistance to chemotherapy, and survival in melanoma.
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Autophagy; Benzenesulfonates; Cell Count; Clinical Trials, Phase II as Topic; Dacarbazine; Drug Resistance, Neoplasm; Humans; Melanoma; Mice; Mice, Nude; Neoplasm Invasiveness; Niacinamide; Phenylurea Compounds; Prognosis; Pyridines; Skin Neoplasms; Sorafenib; Survival Analysis; Temozolomide; Tumor Cells, Cultured; Xenograft Model Antitumor Assays | 2011 |
[News on melanoma from the 2010 Dermatology Days in Paris].
Topics: Antineoplastic Combined Chemotherapy Protocols; Benzenesulfonates; Biomarkers, Tumor; Chemotherapy, Adjuvant; Dacarbazine; Dermatology; Evidence-Based Medicine; Humans; Melanoma; Mutation; Niacinamide; Phenylurea Compounds; Proto-Oncogene Proteins B-raf; Pyridines; Radiotherapy, Adjuvant; Skin Neoplasms; Sorafenib; Temozolomide; Treatment Outcome | 2011 |
Temozolomide toxicity operates in a xCT/SLC7a11 dependent manner and is fostered by ferroptosis.
Topics: Amino Acid Transport System y+; Animals; Antineoplastic Agents, Alkylating; Apoptosis; Astrocytes; Autophagy; Cell Cycle Checkpoints; Cell Line, Tumor; Cell Survival; Dacarbazine; Drug Resistance, Neoplasm; Drug Synergism; Gene Expression; Gene Knockdown Techniques; Glioma; Humans; Mice; Niacinamide; Phenylurea Compounds; Piperazines; Pyramidal Cells; Rats; Sorafenib; Temozolomide | 2016 |
Temozolomide and sorafenib as programmed cell death inducers of human glioma cells.
Topics: Antineoplastic Agents; Apoptosis; Astrocytoma; Cell Line, Tumor; Dacarbazine; Gene Expression Regulation, Neoplastic; Humans; Niacinamide; Phenylurea Compounds; RNA Interference; Sorafenib; Temozolomide | 2017 |